V1RC13 Inhibitors
V1RC13 inhibitors encompass a range of chemical compounds that act upon various signaling pathways to ultimately reduce the activity of the V1RC13 protein. LY294002 and Wortmannin, both PI3K inhibitors, lead to diminished V1RC13 function by curtailing AKT phosphorylation, a key step necessary for V1RC13 activation. Similarly, Triciribine's inhibition of AKT results in a downstream diminishment of V1RC13 activity. Rapamycin exerts its inhibitory effects by targeting mTOR, a component of the mTORC1 complex, which is implicated in V1RC13-related signaling. MEK inhibitors such as PD98059 and U0126 further contribute to the inhibition of V1RC13 by blocking the MAPK/ERK pathway, a route that is essential for the protein's regulated activity. SB203580, a selective inhibitor of p38 MAP kinase, potentially reduces V1RC13 activity by interfering with stress signal pathways that may involve V1RC13.
In addition to these, inhibitors like SP600125, LFM-A13, Dasatinib, PP2, and Imatinib play roles in diminishing V1RC13 activity through their effects on various kinases and signaling molecules that indirectly regulate V1RC13. SP600125, targeting JNK, and LFM-A13, targeting BTK, can decrease V1RC13 activity if it is regulated by pathways that involve these kinases. Dasatinib and PP2, which are inhibitors of the Src family of tyrosine kinases, and Imatinib, a tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR, could lead to reduced V1RC13 function if the protein is associated with these kinases or their downstream signaling processes. Collectively, these inhibitors employ diverse mechanisms to interfere with the pathways essential for V1RC13's functional role in cellular signaling, ensuring a comprehensive approach to the inhibition of this protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, LY294002 blocks the PI3K/AKT signaling pathway. Since V1RC13 activity is modulated by AKT phosphorylation, inhibition of this pathway by LY294002 leads to decreased function of V1RC13 by preventing its phosphorylation and subsequent activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Known to inhibit mTOR (mammalian target of rapamycin), Rapamycin reduces the activity of the mTORC1 complex. V1RC13, involved in downstream signaling of mTOR, is indirectly inhibited as mTORC1 influences a number of cellular processes including translation and cell growth that V1RC13 may be part of. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK, PD98059 prevents the activation of the downstream kinase ERK. As V1RC13 is regulated by the MAPK/ERK pathway, its activity is reduced due to the lack of ERK-mediated signaling events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is involved in cellular responses to stress and inflammation. Inhibition of this kinase can lead to a decrease in V1RC13 activity if V1RC13 is implicated in pathways that are responsive to cellular stress signals mediated by p38. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
As another PI3K inhibitor, Wortmannin decreases PI3K activity leading to reduced AKT signaling. This loss of signaling downregulates V1RC13 activity by preventing necessary phosphorylation events that would activate V1RC13. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK (c-Jun N-terminal kinase), SP600125 reduces JNK-mediated signaling. If V1RC13 is modulated via pathways that involve JNK, such as apoptosis or cellular differentiation, its activity would decrease as a result of JNK inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Specifically inhibiting MEK1/2, U0126 prevents the activation of the MAPK/ERK pathway. Consequently, V1RC13 function is impaired due to the blockade of this essential signaling route that contributes to its activation. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
A selective inhibitor of Bruton's tyrosine kinase (BTK), LFM-A13 impedes BTK-mediated signaling pathways. Should V1RC13 be regulated through BTK-associated pathways, its activity would be indirectly diminished due to the lack of BTK signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
This Src family kinase inhibitor disrupts multiple kinases, including those regulating cell growth and survival pathways. V1RC13, if it interacts with Src family kinases directly or through downstream effects, would experience reduced activity due to Dasatinib's broad kinase inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src kinase inhibitor that specifically blocks the Src family of protein tyrosine kinases. V1RC13 activity, if dependent on Src signaling for activation, would be negatively impacted by PP2's inhibition of Src kinase activity. | ||||||